Shots:

• The approval is based on the P-III PEACHTREE trial to evaluate Xipere in 160 patients with macular edema associated with uveitis. The therapy is expected to be available in Q1'22
• The results showed that the greater proportion of patients treated with Xipere had achieved an improvement in BCVA (47% vs 16%) @24wks. Additionally, safety and efficacy data of Xipere had shown in multiple clinical studies
• Xipere is the 1st therapy to be available in the US & is designed to treat macular edema associated with uveitis via suprachoroidal administration using SCS Microinjector which has been developed by Clearside

Click here to­ read full press release/ article | Ref: PRNewswire  | Image: LinkedIn